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RESEARCH ARTICLE Open Access
Pertussis hospitalizations among term and
preterm infants: clinical course and vaccine
effectiveness
Nicoline A. T. van der Maas1* , Elisabeth A. M. Sanders2, Florens G. A. Versteegh3, Albertine Baauw4,
Anneke Westerhof1 and Hester E. de Melker1
Abstract
Background: Pertussis causes severe disease in young unvaccinated infants, with preterms potentially at highest
risk. We studied pertussis in hospitalized infants as related to gestational age (GA) and vaccination history.
Methods: Medical record data of 0-2y old patients hospitalized for pertussis during 2005–2014 were linked to
vaccination data. Multivariable logistic regression was used to study the association between GA and vaccination
history on the clinical disease course. We compared vaccine effectiveness (VE) against hospitalization for pertussis
between term and preterm infants (i.e., <37w GA) using the screening method as developed by Farrington.
Results: Of 1187 records, medical data from 676 were retrieved. Of these, 12% concerned preterms, whereas they
are 8% of Dutch birth cohorts. Median age at admission was 3 m for preterms and 2 m for terms (p < 0.001).
Preterms more often had received pertussis vaccination (62% vs 44%; p = 0.01) and more often had coinfections
(37% vs 21%; p = 0.01). Preterms tended more often to have complications, to require artificial respiration or to
need admittance to the intensive care unit (ICU). Preterms had longer ICU stays (15d vs 9d; p = 0.004).
Vaccinated preterms and terms had a lower median length of hospital stay and lower crude risks of apneas and the
need for artificial respiration, additional oxygen, and ICU admittance than those not vaccinated. After adjustment
for presence of coinfections and age at admittance, these differences were not significant, except the lower need
of oxygen treatment in vaccinated terms. Effectiveness of the first vaccination against pertussis hospitalizations was
95% (95% CI 93–96%) and 73% (95% CI 20–91%) in terms and preterms, respectively. Effectiveness of the second
dose of the primary vaccination series was comparable in both groups (86 and 99%, respectively).
Conclusions: Infants hospitalized for pertussis suffer from severe disease. Preterms were overrepresented, with
higher need for intensive treatment and less VE of first vaccination. These findings stress the need for alternative
prevention, in particular prenatal vaccination of mothers, to reduce pertussis in both groups.
Keywords: Pertussis, Preterms, Infants, Hospitalization, Vaccine effectiveness, Vaccination
Background
Pertussis is a highly contagious respiratory tract infection,
caused mainly by Bordetella pertussis and less frequently
by Bordetella parapertussis [1]. In the pre-vaccination era,
infants and children contracted pertussis in their first years
of life, with a clinical course characterized by uncontrol-
lable coughing attacks, often accompanied by paroxysms,
post-tussive vomiting, and inspiratory whooping. Consist-
ently high vaccination coverage has substantially decreased
pertussis in the population [2, 3], but newborns too young
to be vaccinated remain at high risk for severe complica-
tions including apnea, cyanosis, pneumonia, encephalop-
athy or even death [4]. This risk is increasing due to the
worldwide pertussis reemergence in the 1990s, even in
areas of high vaccination coverage in all age groups, with
transmission of disease from household members to
newborns. Today, high pertussis incidences in infants are
observed, with incidence peaking every two to three years
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[3, 5, 6]. Worldwide in 2014, an estimated 24 million cases
and 160,000 deaths from pertussis occurred in children
younger than 5 years, with the African region contributing
the greatest share [7]. In the Netherlands, each year ap-
proximately 150–180 children <2y are hospitalized and
one infant, in general too young to be vaccinated, dies due
to pertussis [8]. For this reason, many countries are
discussing prenatal pertussis vaccination of mothers to
protect newborns, and a growing number of countries now
recommend it [9]. This measure is effective in preventing
pertussis in the first months of life and has decreased the
pertussis disease burden in young infants [10, 11]. In the
Netherlands, the Health Council advised that 3rd trimester
maternal pertussis vaccination be offered. This is overall
very effective in prevention of pertussis in early infancy,
but preterms may benefit less due to a smaller time-
window for mother-to-child transfer of antibodies before
delivery [12, 13]. However, vaccine effectiveness (VE) is re-
portedly lower after 2nd trimester pertussis vaccination
[14]. Given the introduction of a maternal vaccination
strategy against pertussis in The Netherlands, we sought to
gain more insight into the current pertussis burden among
hospitalized infants, with special attention to preterms.
Methods
Setting, data collection, and linkage
During the study period (2005–2014), the Netherlands’
National Immunization Programme included a 3 + 1 in-
fant vaccination schedule using pentavalent (2005–2011)
or hexavalent (2012–2014) combination vaccines con-
taining acellular pertussis, with doses at 2, 3, 4 and 11
months of age [15]. Vaccination coverage of the infant
series was 93.5–95.5% for all included birth cohorts [2].
We sent a letter with information about the study aim
and logistics together with an informed consent form to
the boards of all hospitals in the Netherlands. To those
that supplied written approval, we sent a list of all re-
cords selected from the National Registry of Hospital
Care. The relevant medical records were located and
data extracted by trained medical students, supervised
by a medical doctor (NvdM). Besides birth date, sex, and
postal code, data were collected on gestational age (GA)
and birth weight, clinical symptoms at admission, date
of admission and discharge, diagnostics, and details
about the medical situation, complications, treatments,
and clinical status at discharge.
In the National Registry of Hospital Care and the
vaccination registry, which includes all 0–18-year-olds
and any changes in residence, pseudonyms were created
based on birth date, sex, and postal code. For infants
who moved over time, pseudonyms in the vaccination
registry reflected their known postal codes to a max-
imum of six. Using the pseudonyms, medical record data
were linked to the national vaccination registry.
To ensure privacy, a Trusted Third Party was used for
certain steps in data collection and data linking. Re-
searchers were allowed to use age only in months.
Medical ethical approval was not needed because no
one was subjected to imposed rules or acts. According
to Dutch law, informed consent of patients was not
required because the study served public interest, and
asking permission was not feasible [16, 17].
Data sources
National Registry of hospital care
Hospital Care data include the main diagnosis, date of
birth, four digits of the postal code, sex, and date of admis-
sion or outpatient treatment [18]. We located medical
records for 0–2-year-olds with a primary diagnosis of
whooping cough between 2005 and 2014 based on the
International Classification of Diseases (ICD) codes, i.e.,
ICD-9 0330 or ICD-10 A370 (caused by B. pertussis);
ICD-9 0331 or ICD-10 A371 (B. parapertussis); ICD-9
0338 or ICD-10 A378 (other specified organism); or ICD-
9 0339 or ICD-10 A379 (other unspecified organism).
Statistical analysis
Differences in general characteristics and clinical aspects
of pertussis between terms and preterms (defined as
born before 37w GA) were described and tested using
Pearson’s Chi Square or Fisher’s exact test for dichotomous
and categorical variables, and student t-test or Wilcoxon
rank test for continuous variables.
Multivariable logistic regression was performed to as-
sess the association between prematurity and the clinical
picture of pertussis and to study the association between
pertussis vaccination and clinical characteristics strati-
fied by GA. Data for both analyses were adjusted for age
at hospitalization and coinfections.
Vaccine effectiveness (VE), stratified for preterms and
terms, was computed using the screening method as de-
veloped by Farrington [19]. We used monthly cumula-
tive coverage estimates of a timely first dose, stratified
by preterms and terms [20]. In the main analysis, we
classified children without exact GA but with written in-
formation of a term pregnancy and infants without in-
formation on GA as terms. In sensitivity analyses, we
included only children with known GA.
Analyses were performed using SAS version 9.4. A p-
value < 0.05 was considered statistically significant. Fur-
thermore, term infants were set as reference in all analyses.
Results
General descriptives
We invited the participation of 87 hospitals. Of these, 4/8
university hospitals, 19/26 top clinical hospitals, and 27/51
local hospitals participated. Overall, data of 57% of eligible
cases (676/1187) were available.
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Of the 676 hospitalized pertussis cases, 80 infants
(12%; 95%CI 10–14%) were born preterm, 388 (57%)
were born term, and 208 (31%) lacked information on
gestational age (GA) at birth.
Median GA of preterms at birth was 35w (range
26w – 36w). Thirteen (16%) preterms were born be-
fore 32w GA, whereas 67 (84%) were born between
32w – 36w GA.
Among terms and preterms, respectively, 81% and 75%
of medical records could be linked to vaccination data.
Pseudonyms of the remaining records were too unspe-
cific for reliable linkage.
Main analyses (n = 676)
Hospitalization
Median age at hospitalization was 2months (Table 1).
Terms were hospitalized at younger ages than preterms
(median 2.0m vs 3.0m). Median duration of hospitalization
was 5 and 6 days for terms and preterms, respectively.
Overall, 46% of infants were vaccinated at admission, with
statistically significant higher frequencies in preterms
(62%) than in terms (44%; p = 0.01). Among vaccinated
infants, the median interval between first vaccination
and hospitalization was 35d in terms (mean 106d),
compared with 37d in preterms (mean 105d).
Clinical course and treatment
On admittance, 93% of infants were coughing, and
73% also suffered from coughing attacks (Table 1).
Other classical pertussis symptoms such as prolonged
inspiratory effort, whooping, vomiting, and apneas
were reported in up to 35% of infants. Reported symp-
toms at admission did not differ between terms and
preterms, except that cyanosis more often occurred in
terms (44% vs 31%; p = 0.03).
Complications like bradycardia, respiratory insuffi-
ciency and desaturation, feeding problems, weight loss,
and pneumonia were reported in 9% of infants, with a
slightly (not-significant) higher frequency in preterms
(Table 1). Two term infants, too young to be eligible for
vaccination, died due to pertussis.
Before admission, 20% of infants already had re-
ceived antibiotics, whereas 81% received antibiotics
during hospitalization (Table 1). Though preterms
were slightly more often treated with intravenous an-
tibiotics, the start and duration of antibiotics was
comparable between the groups. We also found a
comparable need for additional oxygen (37% vs 34%)
and ICU admittance (13% vs 10%), though a trend to
more often need artificial respiration was observed in
preterms compared to terms (14% vs 7%; p = 0.05).
Duration of ICU stay was longer in preterms than in
terms (median 15 vs 9 days; p = 0.004).
At discharge, 77% of infants still had symptoms, with
coughing most prevalent (Table 1). Likewise, 14%
needed re-admittance within 6 weeks after discharge.
Both frequencies were somewhat lower in preterms
compared to terms.
Diagnostics
For 91% of infants, information on diagnostics to con-
firm pertussis was found in the medical record (Table 1).
In 5% we found evidence of all three diagnostic proce-
dures (i.e., culture, polymerase chain reaction, and ser-
ology), with two procedures in 25% and one procedure
in 64% of infants.
White blood cell (WBC) counts were available for one
third of the medical records; the median highest value
was17.2 (range 4.3–106.1), with somewhat lower values
in preterms (Table 1). Data on C-reactive protein (CRP)
were available for 21% of records, with lower median
CRP in terms than preterms (4.7 vs 15; p = 0.007).
In 53% of the infants, diagnostics were performed for
pathogens other than B. pertussis (Tables 1 and 2).
Overall, preterms were more often tested (61% vs 51%;
p = 0.2) and diagnosed (37% vs 21%; p = 0.01) with
coinfections than terms. Respiratory syncytial virus (RSV),
influenzavirus, adenovirus, human meta-pneumovirus,
para-influenzavirus, rhinovirus, and Mycoplasma pneu-
moniae were observed in 21 to 57% of tested cases,
with RSV and para-influenzavirus more often observed
in preterms (Table 2). In total, tests for 43 pathogens
were performed. Respiratory pathogens are recorded in
Table 2.
Influence of coinfections and age at hospitalization on the
clinical picture
Using multivariable logistic regression analysis, we stud-
ied the association between the clinical course and treat-
ment of pertussis and prematurity. We adjusted for age
at hospitalization and presence of coinfections. Results
were in line with the trends mentioned in previous
results sections (Table 3). With respect to the need for
artificial respiration, the risk among preterms was sig-
nificantly higher than in terms (adjusted Odds Ratio
(OR) 2.8; 95% CI 1.3–6.0). With respect to apnea,
preterms showed an increased risk after adjustment
(OR 1.8; 95% CI 1.0–3.3).
Influence of vaccination and vaccine effectiveness (VE)
Being vaccinated was associated with a reduction in the
median duration of hospitalization among both terms (9
vs 3 days; p < 0.0001) and preterms (13 vs 5 days; p =
0.01). A lower median duration of ICU admission was
found among vaccinated preterms (8 vs20 days; p = 0.1),
but not in terms. Furthermore, the median highest WBC
count was lower in vaccinated terms (p = 0.004), but not
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Table 1 Clinical course, diagnostic tests, and treatment of pertussis in term and preterm infants. Denominator is the number of
infants in the group, which is noted in column headings or the respective cells
Total group (n = 676) Probable and certain
term infants (n = 596)a
Certain term infants
(n = 388)b
Preterm infants (n = 80)
Characteristics of hospitalization, clinical course, and treatment
Boys; n (%)1 335 (49.6%) 295 (49.5%) 185 (47.7%) 40 (50%)
Age in months at admittance; median (range) 2.0 (0–36) 2.0 (0–35) 2.0 (0–35) 3.0 (0–25)c,d
Duration of hospitalization in days; median (range) 5.0 (1–51) 5.0 (1–51) 5.0 (1–51) 6.0 (1–49)
Admission intensive care unit (ICU); n (%) 69 (10.2%) 59 (9.9%) 50 (12.9%) 10 (12.5%)
Duration ICU stay in days; median (range) 9 (2–34) 9 (2–25) 9 (2–25) 15 (8–34)c,d
Vaccinated at admission; n (%) 250/541 (46.2%) 213/481 (44.3%) 130/319 (40.7%) 37/60 (61.7%)c,d
Coughing attacks; n (%) 494 (73.1%) 438 (73.5%) 280 (72.2%) 56 (70.0%)
Apnea; n (%) 110 (16.3%) 92 (15.4%) 71 (18.3%) 18 (22.5%)
Whooping; n (%) 24 (3.6%) 23 (3.9%) 18 (4.6%) 1 (1.3%)
Vomiting; n (%) 238 (35.2%) 210 (35.2%) 146 (37.6%) 28 (35.0%)
Prolonged inspiratory effort; n (%) 49 (7.3%) 42 (7.1%) 33 (8.5%) 7 (8.8%)
Collapse; n (%) 8 (1.2%) 6 (1.0%) 5 (1.3%) 2 (2.5%)
Cyanosis; n (%) 284 (42.0%) 259 (43.5%) 176 (45.4%) 25 (31.3%)c,d
Fever; n (%) 60 (8.9%) 52 (8.7%) 33 (8.5%) 8 (10.0%)
Feeding problems; n (%) 212 (31.4%) 185 (31.0%) 133 (34.3%) 27 (33.8%)
Any complicatione; n (%) 63 (9.3%) 53 (8.9%) 39 (10.1%) 10 (12.5%)
Antibiotics before admissionf; n (%) 131/657 (19.9%) 114/580 (19.7%) 66/377 (17.5%) 18/77 (23.4%)
Antibiotics during admissiong; n (%) 543/674 (80.5%) 475/587 (80.9%) 313/382 (81.9%) 68/78 (87.2%)
Intravenous antibiotics during admission; n (%) 12/403 (3.0%) 9/357 (2.5%) 6/244 (2.5%) 3/46 (6.5%)
Antibiotic use in days; median (range) 6 (0–28) 6 (0–28) 5 (0–28) 5.5 (1–18)
Artificial respiration; n (%) 50/654 (7.7%) 39/577 (6.8%) 32/375 (8.5%) 11/77 (14.3%)c
Additional oxygen; n (%) 226/661 (34.2%) 198/585 (33.9%) 150/382 (39.3%) 28 (36.8%)
Symptoms remaining; n (%) 518 (76.6%) 460 (77.2%) 298 (76.8%) 58 (72.5%)
Re-admittance <6w after discharge; n (%) 94 (14.0%) 85 (14.3%) 56 (14.4%) 9 (11.4%)
Diagnostics
Pertussis test: culture, PCR and serology; n (%) 34 (5.0%) 31 (5.2%) 24 (6.2%) 3 (3.8%)
Pertussis test: culture and PCR; n (%) 59 (8.7%) 52 (8.7%) 40 (10.3%) 7 (8.8%)
Pertussis test: PCR and serology; n (%) 84 (12.4%) 73 (12.2%) 41 (10.6%) 11 (13.8%)
Pertussis test: culture and serology; n (%) 24 (3.6%) 24 (4.0%) 17 (4.4%) 0 (0%)
Pertussis test: culture; n (%) 37 (5.5%) 29 (4.9%) 18 (4.6%) 8 (10%)
Pertussis test: PCR; n (%) 329 (48.7%) 290 (48.7%) 194 (50%) 39 (48.8%)
Pertussis test: serology; n (%) 69 (10.2%) 61 (10.2%) 36 (9.3%) 8 (10%)
Unknown diagnostic test for pertussis; n (%) 40 (5.9%) 36 (6.0%) 18 (4.6%) 4 (5%)
Result white blood cell counting; n (%) 225/476 (47.3%) 200/421 (47%) 141/276 (51.1%) 25/55 (45%)
White blood cell count; median (range) 17.2 (4.3–106.1) 17.7 (5.3–106.1) 17.2 (5.3–74.3) 13.5 (4.3–64.0)
Result C-reactive protein; n (%) 142/392 (36.2%) 119/344 (35%) 81/231 (35.1%) 23/48 (48%)
C-reactive protein; median (range) 5 (0–415) 4.7 (0–415) 5 (0–415) 15 (0–363)c,d
Positive co-infectionsh; n (%) 81/355 (22.8%) 63/306 (20.6%) 46/208 (22.1%) 18/49 (36.7%)c,d
Specification of prescribed antibiotics before admission
Amoxicillin 49/132 (37%) 38/114 (33%) 23/66 (35%) 11/18 (65%)
Azithromycin 24/132 (18%) 21/114 (18%) 17/66 (26%) 3/18 (18%)
Ceftriaxone 1/132 (1%) 1/114 (1%) 1/66 (2%) 0/0
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in vaccinated preterms. In both groups, vaccination was
significantly associated with a lower crude risk of apneas
and the need for artificial respiration, additional oxygen,
or ICU admittance (Table 4). In term infants, vaccin-
ation appeared to reduce the crude risk of complications
and prescription of antibiotics during admission, but the
crude risk of antibiotic prescription before admission
appeared higher among vaccinated terms. After adjust-
ment for coinfections and age at admittance, differences
were no longer significant except for the lower need of
oxygen treatment in vaccinated terms.
Among preterms, VE of the first infant dose (i.e., at 2
months of age) was 73% (95%CI 20–91%) compared to
95% (95% CI 93–96%) among terms (Table 5). Effectiveness
Table 1 Clinical course, diagnostic tests, and treatment of pertussis in term and preterm infants. Denominator is the number of
infants in the group, which is noted in column headings or the respective cells (Continued)
Total group (n = 676) Probable and certain
term infants (n = 596)a
Certain term infants
(n = 388)b
Preterm infants (n = 80)
Clarithromycin 41/132 (31%) 38/114 (33%) 17/66 (26%) 3/18 (18%)
Erythromycin 7/132 (5%) 6/114 (5%) 2/66 (3%) 1/18 (6%)
Feneticillin 1/132 (1%) 1/114 (1%) 1/66 (2%) 0/0
Trimethoprim 1/132 (1%) 1/114 (1%) 1/66 (2%) 0/0
unknown 7/132 (5%) 8/114 (7%) 4/66 (6%) 0/18 (0%)
Specification of prescribed antibiotics during admission
Amoxicillin 11/543 (2%) 10/475 (2%) 7/313 (2%) 1/68 (1%)
Azithromycin 170/543 (31%) 146/475 (31%) 98/313 (31%) 24/68 (35%)
Cephotaxim 1/543 (0.2%) 0/0 0/0 1/68 (1%)
Clarithromycin 314/543 (58%) 280/475 (59%) 184/313 (59%) 34/68 (50%)
Erythromycin 44/543 (8%) 37/475 (8%) 23/313 (7%) 7/68 (10%)
unknown 3/543 (0.6%) 2/475 (0.4%) 1/313 (0.3%) 1/68 (1%)
Specification of reported complications
conjunctivitis 5 (0.7%) 5 (0.8%) 1 (0.3%) 0 (0%)
convulsion 5 (0.7%) 5 (0.8%) 4 (1.0%) 0 (0%)
encephalopathy 1 (0.2%) 1 (0.2%) 1 (0.3%) 0 (0%)
pneumonia 11 (1.6%) 9 (1.5%) 7 (1.8%) 2 (2.5%)
otitis media 1 (0.2%) 1 (0.2%) 0 (0%) 0 (0%)
death 2 (0.3%) 2 (0.3%) 2 (0.5%) 0 (0%)
bradycardia 8 (1.2%) 7 (1.2%) 6 (1.6%) 1 (1.3%)
cardio-respiratory insufficiency 7 (1.0%) 5 (0.8%) 4 (1.0%) 2 (2.5%)
desaturation 20 (3.0%) 18 (3.0%) 14 (3.6%) 2 (2.5%)
feeding problems 5 (0.7%) 2 (0.3%) 0 (0%) 3 (3.8%)
weight loss 12 (1.8%) 11 (1.9%) 8 (2.1%) 1 (1.3%)
dehydration 1 (0.2%) 1 (0.2%) 1 (0.3%) 0 (0%)
need for drip-feed 4 (0.6%) 2 (0.3%) 1 (0.3%) 2 (2.5%)
gastroenteritis 3 (0.4%) 2 (0.3%) 2 (0.5%) 1 (1.3%)
sepsis 1 (0.2%) 1 (0.2%) 0 (0%) 0 (0%)
extreme high white blood cell count 2 (0.3%) 1 (0.2%) 0 (0%) 1 (1.3%)
metabolic alkalosis 1 (0.2%) 1 (0.2%) 0 (0%) 0 (0%)
hypotonia 2 (0.3%) 1 (0.2%) 1 (0.3%) 1 (1.3%)
aterm infants in main analysis
bterm infants in sensitivity analysis
csignificant difference (p < 0.05) between certain+probable terms and preterms (main analysis)
dsignificant difference (p < 0.05) between certain terms and preterms (sensitivity analysis)
eSpecific complications are listed at the end of the table
fSpecification of prescribed antibiotics before admission are listed at the end of the table
gSpecification of prescribed antibiotics during admission are listed at the end of the table
hSpecification of diagnostics for coinfections are listed in Table 2
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of the second dose of the primary vaccination series was
comparable in both groups at 86 and 99%, respectively.
Sensitivity analyses; n = 468
Taking into account only those infants with known GA,
findings were comparable to the main analyses, i.e., ana-
lyses in relation to prematurity (n = 468), vaccination
status (n = 379), and VE estimates (not all data shown)
(Tables 1, 2 and 5).
Discussion
This medical record study on infant pertussis hospital-
izations showed an overrepresentation of preterms,
who accounted for 12% of all pertussis hospitalizations
while comprising, on average, 8% of Dutch birth co-
horts [21]. Furthermore, preterms were older than
terms at hospitalization and had more often received
their first pertussis vaccinations. Effectiveness of this
first dose was significantly lower for preterms than for
terms. Moreover, preterms tended to need more often
intensive treatment and had a longer ICU stay. Like-
wise, preterms tended to be diagnosed more often
with coinfections. Despite lower VE, the first vaccin-
ation against pertussis reduced disease severity and
the need for intensive treatment in both groups. Coin-
fections and age at admission influenced the need for
intensive treatment and mitigated the beneficial effect
of pertussis vaccination.
The overrepresentation of preterms has been reported
in other studies. In Norway, 10% of infant pertussis hospi-
talizations concerned preterms, compared to 5% born pre-
maturely nationwide [22]. Similar data are derived from
England [13], Australia [23], and Canada [24]. Low birth
weight (LBW), which is associated with preterm delivery,
was increased among hospitalized pertussis cases in
Jerusalem [25]. Likewise, Langkamp et al. showed that
LBW infants were at increased risk of pertussis hospitali-
zations compared to those of normal birth weight [26].
Winter et al. reported that LBW and low GA were associ-
ated with increased risk of fatal pertussis [4].
Table 2 Percentages (numbers tested and positive) of pathogens besides B.pertussis causing respiratory symptoms in term and
preterm infants. Denominators are specified per cell
Total group (n = 676) Probable and certain term
infants (n = 596)a
Certain term infants (n = 388)b Preterm infants (n = 80)
Respiratory syncytial virus 21% (62/293) 19% (49/257) 20% (34/169) 36% (13/36)c,d
Influenzavirus 34% (38/112) 31% (29/93) 35% (22/62) 47% (9/19)
Adenovirus 36% (35/98) 33% (27/82) 35% (18/51) 50% (8/16)
Human metapneumovirus 35% (28/81) 32% (22/68) 32% (12/37) 46% (6/13)
parainfluenzavirus 33% (25/76)) 28% (18/65) 28% (12/43) 64% (7/11)c,d
Rhinovirus 57% (40/70) 56% (33/59) 63% (25/40) 64% (7/11)
Mycoplasma pneumoniae 29% (19/65) 27% (15/55) 30% (10/33) 40% (4/10)
Bocavirus 56% (9/16) 42% (5/12) 44% (4/9) 100% (4/4)
Chlamydophila pneumoniae 41% (12/29) 48% (12/25) 60% (9/15) 0% (0/4)
Chlamydia psittaci 0% (0/1) 0% (0/1) not tested not tested
Cytomegalovirus 33% (4/12) 22% (2/9) 33% (2/6) 67% (2/3)
Coronavirus 56% (18/32) 50% (14/28) 56% (9/16) 100% (4/4)
Coxiella burnetii 0% (0/7) 0% (0/6) 0% (0/4) 0% (0/1)
Enterovirus 39% (9/23) 42% (8/19) 40% (6/15) 25% (1/4)
Haemophilus influenzae 75% (3/4) 75% (3/4) 100% (3/3) not tested
Klebsiella oxytoca 100% (1/1) not tested not tested 100% (1/1)
Klebsiella pneumoniae 100% (2/2) 100% (1/1) 100% (1/1) 100% (1/1)
Legionella 43% (3/7) 50% (3/6) 60% (3/5) 0% (0/1)
Moraxella catarrhalis 100% (5/5) 100% (4/4) 100% (3/3) 100% (1/1)
Bordetella parapertussis 0% (0/5) 0% (0/3) 0% (0/3) 0% (0/2)
Parechovirus 0% (0/3) 0% (0/2) 0% (0/2) 0% (0/1)
Streptococcus pneumoniae 100% (3/3%) 100% (1/1) 100% (1/1) 100% (2/2)
aterm infants in main analysis
bterm infants in the sensitivity analysis
csignificant difference between certain+probable terms and preterms (main analysis)
dsignificant difference between certain terms and preterms (sensitivity analysis)
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The clinical picture in our observational study resembles
findings in other retrospective studies. Marshall et al.
showed that preterms had a higher pertussis disease sever-
ity score (defined by a longer hospital stay, ICU admittance,
need for rehydration, respiratory support, coinfections, and
the presence of complications) than terms [23]. In England,
a longer duration of hospitalization and higher frequencies
of ICU admittance and coinfections were observed among
preterms, although their frequency of coinfections was
lower than we found (10% vs 37%) [13].Langkamp et al. re-
ported a higher median age at hospitalization and a longer
median length of stay among LBW infants than among
those of normal birth weight [26].
Compared to our study, more active and prospective
study designs have revealed higher frequencies of clinical
characteristics in infants hospitalized for pertussis (both
term and preterm) like cyanosis/desaturation (72%) and
apnea (33%) at admittance [25]. Australian researchers
observed higher rates of ICU admittance (18%) and
treatment with antibiotics (96%) but lower median
length of ICU stay (6 days) [27]. In Switzerland, hospital-
ized infants < 6 m of age had higher frequencies of
coughing attacks (93%), whooping (69%), vomiting (59%)
and complications (24%) [28, 29]. As active designs usu-
ally profit from more structured clinical observations
and documentation in the medical record, the frequen-
cies found in retrospective studies probably underesti-
mate the pertussis burden in terms and preterms [30].
The aim of vaccination against pertussis is to prevent
severe disease. Our study confirms that vaccination re-
duced disease severity and duration of hospitalization, in
line with findings in other countries [27, 31–33] and find-
ings in the Netherlands in 2006–2008 [6]. However, VE
was found to be higher in our study than, for example,
studies in Germany (VE 68%; 95%CI 46–81) and New
Zealand (VE 43%; 95%CI 21–58) report [34, 35]. Unfortu-
nately, no data on GA were provided in those studies. In
Scandinavia, the VE of the first pertussis vaccination
against hospitalization did not differ between terms and
preterms, being 61% vs 71% in Norway and 51% vs 45% in
Denmark [22, 36]. Both countries start their immunization
schedule at age 3months as compared to the Netherlands,
where it occurs between 6 weeks to 2months.
In 2-month-olds, protective maternal antibodies may
be higher than in 3-month-olds, and higher in terms
than in preterms [37]. Likewise, studies have shown a
Table 3 Multivariable logistic regression analyses of the association between premature delivery and clinical course and treatment
of pertussis; crude and adjusted OR and 95% confidence intervals (95%CI)
Probable and certain
term infants (n = 596)a,b
Preterm infants (n = 80)b Crude OR (95% CI) Adjusted OR (95% CI)c
Symptoms at admission
Coughing attacks 438 (73.5%) 56 (70.0%) 0.8 (0.5–1.4) 0.8 (0.5–1.4)
Apnea 92 (15.4%) 18 (22.5%) 1.6 (0.9–2.8) 1.8 (1.0–3.3)
Whooping 23 (3.9%) 1 (1.3%) 0.3 (0.04–2.4) 0.3 (0.04–2.3)
Vomiting 210 (35.2%) 28 (35.0%) 1.0 (0.6–1.6) 1.0 (0.6–1.6)
Prolonged inspiratory effort 42 (7.1%) 7 (8.8%) 1.3 (0.5–2.9) 1.2 (0.5–2.7)
Collapse 6 (1.0%) 2 (2.5%) 2.5 (0.5–12.7) 3.8 (0.7–19.7)
Cyanosis 259 (43.5%) 25 (31.3%) 0.6 (0.4–1.0) 0.7 (0.4–1.1)
Fever 52 (8.7%) 8 (10.0%) 1.2 (0.5–2.6) 0.9 (0.4–2.0)
Feeding problems 185 (31.0%) 27 (33.8%) 1.1 (0.7–1.9) 1.1 (0.7–1.9)
Complications
Any complication 53 (8.9%) 10 (12.5%) 1.5 (0.7–3.0) 1.6 (0.8–3.4)
Treatment
Antibiotics before admission 114/580 (19.7%) 18/77 (23.4%) 1.1 (0.6–2.0) 1.1 (0.6–1.9)
Antibiotics during admission 475/587 (80.9%) 68/78 (87.2%) 1.5 (0.7–3.2) 1.8 (0.9–3.9)
Artificial respiration 39/577 (6.8%) 11/77 (14.3%) 2.3 (1.1–4.8) 2.8 (1.3–6.0)
Additional oxygen 198/585 (33.9%) 28 (36.8%) 1.1 (0.7–1.9) 1.3 (0.8–2.2)
Admission intensive care unit (ICU) 59 (9.9%) 10 (12.5%) 1.3 (0.6–2.7) 1.6 (0.8–3.6)
Discharge
Symptoms remaining 460 (77.2%) 58 (72.5%) 0.8 (0.5–1.3) 0.8 (0.5–1.4)
Term infants are set as reference. Significant results are in bold
aterm infants in main analysis
bIf denominator is different, it is reported in the cell
cadjusted for coinfections and age in months at admission
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decreased immune response after immunization at 2
months in preterms compared with terms [38, 39] while
finding an equal response at 3 months [40]. The fact that
the Scandinavian countries saw no difference in VE be-
tween term and preterms might be explained by the
interplay between maternal antibodies that reduce a first
response and an immune response that is ineffective in
preterms at age 2months but may have improved by age
3 months [41]. For the 2nd dose, we found no VE differ-
ence between terms and preterms.
As in other studies, we found that the effect of vaccin-
ation on the clinical course was influenced by coinfec-
tions [13, 23], which included viral infections like RSV
[42–47]. However, a recent systematic review concluded
that the influence of coinfections on pertussis disease
severity remains unclear [48].
Our study has several strengths. It used nationwide
data collected over a 10-year period. The data contained
detailed information on clinical characteristics of pertus-
sis, also including information on possible confounding
factors, e.g., coinfections. Furthermore, linkage to the vac-
cination registry enabled us to use validated vaccination
records. Finally, the vast majority of the included pertussis
cases were laboratory confirmed.
Limitations of our study include the retrospective
design and the institutional differences in pertussis diag-
nostics, diagnostics for coinfections, and registration of
clinical and laboratory disease characteristics. The 50%
participation rate of hospitals might have influenced our
results, but participating hospitals were spread over the
country and showed a good representation of tertiary,
top clinical, and local hospitals in the Netherlands. Re-
sults might have been influenced by the incomplete
reporting of hospital diagnoses at discharge, assessed in
a recent capture-recapture analysis [8]. We could not
stratify this underreporting by GA, but the good repre-
sentation of tertiary, top clinical, and local hospitals in
our study probably led to inclusion of a representative
variety in the spectrum of pertussis disease. This conclu-
sion is underlined by our finding that preterms are over-
represented, as found by other studies.
Further limitations include the retrospective use of
medical records, which led to missing data, e.g., on GA,
birth weight, with possible impact on our results. For
this reason our main analysis was based on all records,
assuming that infants with unknown GA were born
term. Our sensitivity analysis showed no major impact
of missing data on GA, thereby confirming our findings.
A breakdown of preterms into smaller groups based on
GA would be clinically relevant, but low numbers pro-
hibited this analysis. Likewise, WBCs and CRP data were
incomplete, also leading to less informative results.
Linkage between medical records and vaccination data,
based on pseudonymization, might have led to error. Med-
ical records include the home address at the patient’s last
visit, whereas the vaccination registry includes the current
home address. Especially in cases of frequent moving and/
or a large interval since the last visit, linkage might be in-
correct. In our study, 38% of infants did not move house.
Furthermore, the use of additional pseudonyms based on
previous home addresses (also stored in the vaccination
registry) lowered the risk of incorrect linking.
Table 5 Number of infants vaccinated at admission, monthly cumulative coverage estimates, and VE against pertussis
hospitalizations of 1st and 2nd infant dose for preterm and term infants, assessed with the screening method
















0 m 0% (0/1) na na 0% (0/1) na na
1 m 1.4% (2/144) 1.9% na 0% (0/14) 1.3% na
2m 34.2% (52/152) 90.9% 95%b (93–96%) 60% (9/15) 84.9% 73%b
(20–91%)
3 m 85.9% (67/78) 98.8% 93% (85–96%) 86.7% (13/15) 97.9% 86%
(9–96%)
4 m 93.8% (30/32) 99.4% 91% 100% (4/4) 99.4% na
Sensitivity analysis
0 m 0% (0/1) na na 0% (0/1) na na
1 m 0.9% (1/115) 1.9% na 0% (0/14) 1.3% na
2m 33.7% (33/98) 90.9% 95%b (92–97%) 60% (9/15) 84.9% 73%b (20–91%)
3 m 89.4% (42/47) 98.8% 90% (71–96%) 86.7% (13/15) 97.9% 86% (9–96%)
4 m 100% (14/14) 99.4% na 100% (4/4) 99.4% na
aaccording to the screening method
bsignificant difference between term and preterm infants
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Conclusion
Preterms were overrepresented among pertussis hospi-
talizations and had a slightly higher overall risk of com-
plications, increased need for intensive treatment, and
lower effectiveness of the first infant pertussis vaccin-
ation. The Dutch Health Council recommended mater-
nal pertussis vaccination in the 3rd trimester of
pregnancy. While this strategy is overall very effective,
preterms may benefit less due to less protective maternal
antibody transfer before delivery [12, 13]. They probably
will benefit more from 2nd trimester immunization. Es-
pecially for infants born of unvaccinated mothers, a
timely first post-natal dose remains important, as it
greatly reduces cases of pertussis and decreases disease se-
verity. Our study underlines the need for more in-depth
surveillance of vaccine-preventable diseases in relation to
GA and more insight into optimizing the vaccination pro-
gram for all children but in particular for preterms, the
most vulnerable group.
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